Business News
Financial news, mergers and acquisitions, partnerships, and alliances.
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy while Personalis completes its clinical validation in more indications.
Candel Therapeutics Lays off Half its Workforce, Refocuses on Most Advanced Oncology Programs
By reducing staff and lowering its operating costs, Candel expects to fund operations into the fourth quarter of 2024.
Vertex Nets European Label Expansion for Kaftrio Combo in Younger Cystic Fibrosis Patients
Vertex is also seeking to expand the Kaftrio-Kalydeco combination to cystic fibrosis patients with non-F508del Kaftrio-responsive CFTR mutations.
Arvinas Aims to Raise $350M in Private Placement of Common Stock
The firm developing several precision cancer drugs is selling 12,963,542 shares of common stock and pre-funded warrants to purchase 3,422,380 shares of common stock.
Syncona Taking Freeline Therapeutics Private; Providing $15M in Financing
The additional funds will allow the company to continue to study its gene therapy in Gaucher disease and GBA1-linked Parkinson's disease.